Get the Stockscreener App
4.00
2.44%
-0.09
Black Diamond Therapeutics Inc stock is traded at $4.00, with a volume of 555.67K.
It is down -2.44% in the last 24 hours and up +22.77% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$4.09
Open:
$4.17
24h Volume:
555.67K
Relative Volume:
0.59
Market Cap:
$227.62M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-2.1277
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+1.79%
1M Performance:
+22.77%
6M Performance:
+187.05%
1Y Performance:
+19.82%
1-Day Range:
$3.91
$4.20
1-Week Range:
$3.81
$4.38
52-Week Range:
$1.195
$4.38
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
3.9979 | 232.87M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.12 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.81 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
How geopolitical tensions affect Black Diamond Therapeutics Inc. stockQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Using RSI to spot recovery in Black Diamond Therapeutics Inc.Jobs Report & Community Consensus Trade Signals - newser.com
Black Diamond Therapeutics (BDTX): Valuation Insights After Surging Interest From Strong Earnings and Growth Momentum - Yahoo Finance
Black Diamond Therapeutics Inc Stock Analysis and ForecastPrice Momentum Alerts & Get Peace of Mind with Portfolio Health Checks - earlytimes.in
Why Black Diamond Therapeutics Inc. is moving todayRisk Management & Verified Technical Signals - newser.com
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
Applying Elliott Wave Theory to Black Diamond Therapeutics Inc.2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Black Diamond Therapeutics' (BDTX) Sell (D) Rating Reaffirmed at Weiss Ratings - MarketBeat
Black Diamond Therapeutics Hits New 52-Week High of $4.11 - Markets Mojo
Black Diamond Therapeutics Hits New 52-Week High at $3.90 - Markets Mojo
BDTX Stock Hits 52 Week High: Is There More Room for Growth? - sharewise.com
How to use Fibonacci retracement on Black Diamond Therapeutics Inc.2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
How to escape a deep drawdown in Black Diamond Therapeutics Inc.2025 Market Overview & Risk Managed Trade Strategies - newser.com
Will Black Diamond Therapeutics Inc. stock recover faster than market2025 Geopolitical Influence & Consistent Profit Trading Strategies - newser.com
Using Bollinger Bands to evaluate Black Diamond Therapeutics Inc.July 2025 Highlights & Free Long-Term Investment Growth Plans - newser.com
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Black Diamond Therapeutics Hits New 52-Week High at $4.03 - Markets Mojo
Will Black Diamond Therapeutics Inc. stock benefit from infrastructure spendingQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Published on: 2025-10-05 06:35:20 - newser.com
Technical signs of recovery in Black Diamond Therapeutics Inc.July 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
Published on: 2025-10-03 07:14:35 - newser.com
Why analysts upgrade Black Diamond Therapeutics Inc. stockMarket Growth Summary & Community Consensus Picks - newser.com
Smart tools for monitoring Black Diamond Therapeutics Inc.’s price actionWeekly Volume Report & Daily Profit Focused Screening - newser.com
Published on: 2025-10-03 00:58:16 - newser.com
Published on: 2025-10-02 23:04:01 - newser.com
Visual trend scoring systems applied to Black Diamond Therapeutics Inc.July 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Black Diamond Therapeutics (BDTX) Has a New Rating from Freedom Capital Markets - The Globe and Mail
Published on: 2025-10-01 08:07:11 - newser.com
Regression analysis insights on Black Diamond Therapeutics Inc. performance2025 Support & Resistance & Stock Market Timing Techniques - newser.com
Black Diamond Therapeutics stock initiated with Buy rating at Freedom Capital - Investing.com Canada
Promising Penny Stocks To Watch In September 2025 - Yahoo Finance
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):